Skip to main content

ImClone Systems


is expected to announce Monday that it is continuing talks to sell itself to a major pharmaceutical company for about $6.1 billion, according to people familiar with the matter, the

Wall Street Journal


Last week, ImClone Chairman

Carl Icahn


Bristol-Myers Squibb's


hostile tender offer for $62 a share as "misleading" and "absurd." BioTalk: IMCL, BMY

var config = new Array(); config<BRACKET>"videoId"</BRACKET> = 1815780060; config<BRACKET>"playerTag"</BRACKET> = "TSCM Embedded Video Player"; config<BRACKET>"autoStart"</BRACKET> = false; config<BRACKET>"preloadBackColor"</BRACKET> = "#FFFFFF"; config<BRACKET>"useOverlayMenu"</BRACKET> = "false"; config<BRACKET>"width"</BRACKET> = 265; config<BRACKET>"height"</BRACKET> = 255; config<BRACKET>"playerId"</BRACKET> = 1243645856; createExperience(config, 8);

Icahn reiterated to Bristol-Myers Chairman James Cornelius that a large, unnamed pharmaceutical company has bid $70 a share, subject to due diligence until Sept. 28.



reports ImClone is expected to announce a deadline Monday by which it hopes to have a deal with its other suitor. The two sides remain in "deep discussions" and believe they can reach a resolution within days.

ImClone is best known for its Erbitux cancer drug, Bristol-Myers sells ImClone's Erbitux cancer treatment in the U.S.

ImClone hasn't identified the company it has been holding talks with but speculation has swirled around



, the Journal reports.

Eli Lilly


also has been named as a possible suitor.

Shares of ImClone closed Friday at $63.38.

This article was written by a staff member of